Loading…
← CockpitCompetitor Analysis › 300314.SZ Ningbo David Medical Device Co., Ltd. Class AOpen in the cockpit ↗

Ningbo David Medical Device Co., Ltd. Class A300314.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 98
Mkt cap
$589M
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$23.6M
20-day average traded
Fwd P/E
12.0×
forward earnings
ROIC−WACC
+2.5 pp
WACC 7.6%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥13.89
1D-2.9%
1W-6.6%
1M+5.0%
3M+19.8%
6M+25.4%
YTD+10.4%
1Y+2.4%
ATR %6.0%
52w lowhigh17.8% off high

What Ningbo David Medical Device does

Employees: 920

Ningbo David Medical Device at a glance

Size Ningbo David Medical Device (300314.SZ) is a China Health Care company (Medical Specialties) with a market value of $589M, the 3295th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥13.89 on 18 Nov 2026.

Performance Over six months the shares gained 25.4%, against -12.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 19 in its peer set.

Growth Revenue grew 18.6% over the last twelve months (peer median +6.5%); the operating margin is 11.4% (peer median 7.4%).

Valuation It trades at 12.0× forward earnings against a peer median of 27.7× (2nd cheapest of 11).

Capital Return on invested capital runs 2.5 points above its cost of capital (7.6% WACC).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026300314.SZ 124Peer median 89
Six months, rebased to 100: Ningbo David Medical Device against the median of its 20 peers (local-currency closes).

Ningbo David Medical Device financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥613MCN¥581MCN¥524MCN¥613MCN¥502M
Revenue growth—+11%-14%+22%—
Gross profitCN¥317MCN¥298MCN¥281MCN¥337MCN¥278M
EBITDAn/aCN¥99.6MCN¥86.5MCN¥154MCN¥111M
Net incomeCN¥92.1MCN¥87.1MCN¥57.3MCN¥148MCN¥97.4M
Free cash flow-CN¥57.7MCN¥49.4M-CN¥38.8MCN¥112MCN¥73.2M
Capital expenditureCN¥31.9MCN¥55.0MCN¥140MCN¥40.4MCN¥49.8M
Total debtCN¥4.60MCN¥6.01MCN¥8.82MCN¥13.7MCN¥14.5M

Quarterly statements and history in the cockpit →

Ningbo David Medical Device competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%688581OBIOTCMDSGHTMEDINAN300952PACBXVIVO3012356031226882364728300869ZJYLMYGN300314.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Ningbo David Medical Device is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%50×100×688581TCMDMEDINAN300952XVIVO3012356882366053691789300314.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ningbo David Medical Device is the large dot.

Ningbo David Medical Device competitors and peer comparison

How Ningbo David Medical Device compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ningbo David Medical Device against its 20 peers (data as of 18 Nov 2026)
Measure300314.SZPeer medianRank in peer set
1-month return+5.0%-1.9%6th highest of 19
6-month return+25.4%-12.6%7th highest of 19
Distance from 52-week high-17.8%-34.3%6th highest of 20
Revenue growth (TTM)+18.6%+6.5%6th highest of 20
Operating margin11.4%7.4%7th highest of 20
Forward P/E12.0×27.7×2nd cheapest of 11
ROIC minus cost of capital+2.5 pp-3.3 pp7th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%17.4×-8.5%+2.2%
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Jin Medical International ZJYLUnited States$532M+47%-14%2%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a

Questions

Which companies are Ningbo David Medical Device's closest peers?
The cockpit's peer set: Hangzhou AGS MedTech (688581.SS), Orchestra BioMed (OBIO), Tactile Systems Technology (TCMD), vVARDIS (VVVV), Sahajanand Medical Technologies (SMT.NS), Sight Sciences (SGHT), Medistim (MEDI.OL), Nanosonics (NAN.AX).
Is Ningbo David Medical Device expensive compared with its peers?
On forward p/e it trades at 12.0× against a peer median of 27.7×, 2nd cheapest of 11 in its peer set.
How has Ningbo David Medical Device stock performed?
Over six months to 18 Nov 2026 the shares returned +25.4% against -12.6% for the median peer; over one year +2.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.